Merck & Co. Eyes Neuroscience Advancement With US FDA’s New Receptivity To Biomarkers

 
• By Brenda Sandburg

Company is ‘anxious to understand’ how to utilize the agency’s views on importance of biomarkers, exec notes in earnings call. Merck & Co. and Pfizer advance COVID-19 therapeutics into Phase III. Pfizer is awaiting FDA risk-benefit assessment of JAK-1 inhibitors Xeljanz and abrocitinib.

Neuroscience
Merck & Co. notes changing regulatory landscape on use of biomarkers in neuroscience drug development • Source: Alamy

More from Clinical Trials

More from R&D